Rexahn Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. The company's cancer drugs have been shown to directly target cancer cells while bypassing healthy cells, demonstrating increased efficacy and reduced toxicity. These drug candidates are effective against multiple drug-resistant cancers and show they can work together with FDA-approved cancer treatments to increase efficacy. Rexahn is also developing specific biomarkers that identify which patients will be most responsive to its treatments. The company's nanotechnology-based drug delivery system has shown it can make FDA approved chemo drugs more effective.